# India Porokeratosis Market > India Porokeratosis Market Research Report By Type (DSAP, Linear Porokeratosis, Peoddn, Others) and By Diagnosis & Treatment (Biopsy, 5-Fluorouracil, Photodynamic Therapy, Retinoids, Cryotherapy, Lasers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.14% - **2024:** $ 48.4 Million - **2025:** $ 53.79 Million - **2035:** $ 154.64 Million - **Key Players:** Amgen Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Pfizer Inc (US), Sanofi S.A. (FR), Mylan N.V. (US), Galderma S.A. (CH) **Report ID:** MRFR/HC/54310-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-porokeratosis-market-56076 --- ## Market Summary ## **India Porokeratosis Market Overview** As per MRFR analysis, the India Porokeratosis Market Size was estimated at 46.4 (USD Million) in 2024.The India Porokeratosis Market Industry is expected to grow from 48.4(USD Million) in 2025 to 190 (USD Million) by 2035. The India Porokeratosis Market CAGR (growth rate) is expected to be around 13.238% during the forecast period (2025 - 2035). **Key India Porokeratosis Market Trends Highlighted** The India Porokeratosis Market is witnessing significant trends driven by various factors. An increasing awareness regarding skin diseases and disorders, along with the availability of advanced healthcare facilities, is propelling market growth. Porokeratosis, being a rare skin condition, has become a focal point for dermatologists, prompting the need for effective treatment options and specialized care. The rise in skin-related issues, especially in urban areas, reflects a growing demand for dermatological treatments.  Opportunities in the market are shaped by the continuous research efforts aimed at better understanding and treating porokeratosis.The Indian government has initiated programs to improve healthcare infrastructure, which includes enhancing dermatology services. This creates a fertile ground for businesses to develop and introduce innovative therapeutic solutions. Additionally, collaboration between pharmaceutical companies and research institutions can facilitate the discovery of new treatment modalities, enhancing patient outcomes. Trends in recent times indicate a shift towards personalized medicine and targeted therapies for managing porokeratosis.  The increase in the adoption of biologics and other novel therapies showcases a changing preference in treatment approaches.Furthermore, digital health solutions are gaining traction, with telemedicine providing patients access to specialist care, especially in rural areas. As awareness spread, especially through social media campaigns, more patients are seeking help for skin conditions, including porokeratosis, thereby contributing to market growth. Overall, the confluence of heightened awareness, robust healthcare initiatives, and technological advancements is shaping the future landscape of the India Porokeratosis Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Porokeratosis Market Drivers** **Increasing Awareness of Skin Diseases** In India, there has been a significant rise in the awareness of skin diseases, including porokeratosis. Campaigns led by associations such as the Indian Association of Dermatologists, Venereologists, and Leprologists have played a pivotal role in educating the public. This increase in awareness has been reflected in the higher number of dermatology consultations, rising from 25 million in 2019 to an estimated 35 million in 2023, according to regional health reports. As people become aware of the condition and try to get help, the demand for porokeratosis-specific items and treatments will grow, which will take the India Porokeratosis Market Industry to new heights. Furthermore, the development of several telemedicine services has also improved access to dermatologist services, which has helped in market growth prospects. **Growing Pharmaceutical Investments in Dermatology** The pharmaceutical sector in India is witnessing increased investments, particularly in dermatological treatments. As per the Department of Pharmaceuticals, Government of India, the dermatology segment is projected to receive a 15% increase in funding over the next five years. Major pharmaceutical companies are actively investing in Research and Development (R&D) for innovative treatments addressing skin conditions, including porokeratosis.  These investments are essential for developing new formulations and therapies, which can significantly enhance customer accessibility and efficacy.This surge in R&D is expected to retire numerous existing patents and bring forth novel solutions to the market, thus compelling the growth of the India Porokeratosis Market Industry. **Rising Prevalence of Skin Disorders** The increase in skin disorders, attributed to factors such as pollution, changing lifestyles, and increased sun exposure, is becoming a significant driver for the India Porokeratosis Market Industry. According to a report published by the Ministry of Health and Family Welfare, skin diseases affect approximately 30% of the Indian population, which translates to nearly 400 million individuals.  This high prevalence creates a substantial demand for dermatological services and treatments.The growing recognition of porokeratosis as a unique dermatological condition will pave the way for more specialized treatments and increase the therapeutic options available in the Indian market. As a result, pharmaceutical companies are motivated to develop new products targeting this condition. **India Porokeratosis Market Segment Insights** **Porokeratosis Market Type Insights** The India Porokeratosis Market demonstrates a diverse range of types essential to understanding the industry's dynamics. Among these types, Disseminated Superficial Actinic Porokeratosis (DSAP) stands out as a prevalent form, noted for its significant occurrence in individuals with a history of sun exposure, primarily affecting older populations in India. Linear Porokeratosis, while less common, showcases a unique pattern that typically arises in a linear distribution, making it particularly interesting for dermatological research given its distinctive presentation.The Peoddn type, marked by its specific genetic predispositions, underscores the importance of genetic research in understanding the etiology of Porokeratosis, which can lead to personalized treatment approaches tailored for affected individuals.  Other forms in the India Porokeratosis market also contribute to this diversified landscape by presenting a variety of clinical manifestations, further extending the scope of treatment options and driving demand for advanced dermatological therapies. This segmentation not only highlights the complexity of Porokeratosis but also points to opportunities for targeted therapies that address the unique challenges posed by each type. Understanding the segmentation within the India Porokeratosis Market is essential for stakeholders, including healthcare providers and pharmaceutical companies, to develop effective strategies that cater to the varying needs of patients across the region. With increasing awareness and advancements in dermatological treatments, each type presents unique opportunities to improve patient outcomes, driving significant growth in the market as it becomes increasingly important for clinicians to differentiate between these types for optimal diagnosis and management. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Porokeratosis Market Diagnosis & Treatment Insights** The Diagnosis and Treatment segment of the India Porokeratosis Market plays a pivotal role in addressing the healthcare needs related to this skin condition. This segment encompasses various options, including Biopsy, which is crucial for accurate diagnosis as it helps determine the presence and nature of porokeratosis. Additionally, 5-Fluorouracil remains a widely considered option for its effectiveness in treatment protocols aimed at reducing lesions. Photodynamic Therapy is gaining traction for its minimally invasive nature, providing patients with an effective solution that minimizes recovery time. Moreover, Retinoids are often recommended due to their ability to promote skin cell turnover, thereby aiding in the management of symptoms. Cryotherapy and Lasers are significant minimally invasive modalities that not only improve the appearance of skin lesions but also enhance patient comfort and satisfaction. Collectively, these tactics reflect a move towards personalized care in dermatology, with increased emphasis on safety and efficacy driven by advancements in technology. The growing awareness about skin disorders, supported by initiatives related to dermatological health in India, further propels the demand for these treatment avenues, showcasing the potential for substantial market growth.The segment's diversification underscores its importance in promoting enhanced patient outcomes through innovative treatments. **India Porokeratosis Market Key Players and Competitive Insights** The India Porokeratosis Market is experiencing notable attention, driven by increasing prevalence rates and a growing awareness of dermatological conditions among the population. This segment of the healthcare industry is characterized by an expanding range of treatment options, innovative therapies, and heightened research activities focused on understanding and managing the condition more effectively. The competitive landscape is marked by the presence of both established pharmaceutical companies and emerging players, contributing to a dynamic market that fosters product diversity and technological advancements. Additionally, factors such as regulatory frameworks, market accessibility, and changing consumer preferences are shaping the strategies adopted by these companies to capture a significant share of this growing market. Lupin has developed a strong reputation within the India Porokeratosis Market through its commitment to high-quality pharmaceutical products and innovative research. The company leverages its extensive experience in dermatological formulations to offer effective treatments for porokeratosis and similar skin conditions. One of Lupin's key strengths lies in its robust research and development framework, allowing it to stay ahead of competitors by introducing advanced therapeutic options. Furthermore, Lupin's established distribution network across India ensures that its products are accessible to healthcare professionals and patients alike. This widespread presence in various therapeutic segments, combined with a strong focus on quality assurance, helps reinforce Lupin's position in the market, making it a trusted name in the treatment of porokeratosis. Intas Pharmaceuticals is another key player in the India Porokeratosis Market, known for its diverse portfolio of dermatological products. The company has made significant investments in research and development to develop targeted treatments for porokeratosis and has consequently expanded its footprint in this niche market. Intas excels in the timely introduction of new formulations, capitalizing on its research capabilities to meet unmet medical needs. The company’s strengths include a strong manufacturing infrastructure and adherence to international quality standards, allowing it to deliver consistent and effective medications. Strategic mergers and acquisitions have further bolstered Intas's market presence, enabling it to enhance its research capabilities and expand its product offerings. This proactive approach has facilitated Intas's growth and solidified its reputation as a leading provider of therapies for porokeratosis within India. **Key Companies in the India Porokeratosis Market Include:** - Lupin - Intas Pharmaceuticals - Alembic Pharmaceuticals - Hetero Labs - Zydus Cadila - Dr. Reddy's Laboratories - Torrent Pharmaceuticals - Emcure Pharmaceuticals - Biocon - Asterisk Healthcare - Macleods Pharmaceuticals - Sun Pharmaceutical Industries - Wockhardt - Cipla **India Porokeratosis Market Industry Developments** Recent developments in the India Porokeratosis Market have shown an increased focus on innovative treatment options and heightened awareness about the condition. Companies such as Lupin, Intas Pharmaceuticals, and Dr. Reddy's Laboratories have been working towards enhancing their product portfolios, incorporating advanced formulations aimed at treating Porokeratosis.  The market has also observed a significant growth trajectory, with noteworthy financial valuations increasing for pharmaceutical companies engaged in dermatological treatments. In September 2023, Hetero Labs announced a collaboration with a leading research institution to advance Drug Development in the dermatological space, emphasizing the importance of research and scientific innovation.  Additionally, in August 2023, Zydus Cadila launched a specialized formulation aimed at managing Porokeratosis, reflecting their commitment to expanding treatment options. There have been minimal merger or acquisition activities directly related to companies in this niche sector in recent months, indicating a stable competitive landscape. In 2022, the market gained momentum as various organizations conducted extensive awareness programs to educate healthcare professionals about Porokeratosis, reinforcing the significance of early diagnosis and treatment in India. **India Porokeratosis Market Segmentation Insights** **Porokeratosis Market Type Outlook** - DSAP - Linear Porokeratosis - Peoddn - Others **Porokeratosis Market Diagnosis & Treatment Outlook** - Biopsy - 5-Fluorouracil - Photodynamic Therapy - Retinoids - Cryotherapy - Lasers - Others ## Market Drivers ### Government Initiatives and Support Government initiatives aimed at improving healthcare access and awareness are significantly impacting the porokeratosis market in India. Various health programs and campaigns have been launched to educate the public about skin diseases, including porokeratosis. The Indian government has allocated substantial funding to enhance dermatological services and research, which is expected to lead to better diagnostic tools and treatment options. For instance, the National Health Mission has been instrumental in promoting skin health awareness, which may result in increased patient visits to dermatologists. This proactive approach by the government not only fosters a supportive environment for patients but also encourages pharmaceutical companies to invest in research and development for effective treatments, thereby propelling the porokeratosis market forward. ### Increasing Incidence of Porokeratosis The rising incidence of porokeratosis in India is a crucial driver for the porokeratosis market. Recent studies indicate that the prevalence of skin disorders, including porokeratosis, has been on the rise, with estimates suggesting that around 1-2% of the population may be affected. This increase is likely attributed to various factors, including environmental influences and genetic predispositions. As more individuals are diagnosed, the demand for effective treatment options and dermatological services is expected to grow. Consequently, healthcare providers are focusing on enhancing their capabilities to address this condition, thereby stimulating the porokeratosis market. The heightened awareness among healthcare professionals regarding the condition is also contributing to early diagnosis and treatment, which may further drive market growth. ### Technological Advancements in Dermatology Technological advancements in dermatology are playing a pivotal role in shaping the porokeratosis market. Innovations such as teledermatology and advanced imaging techniques are enhancing the diagnosis and management of skin conditions. In India, the adoption of digital health solutions is increasing, allowing for remote consultations and improved patient access to dermatological care. This trend is particularly beneficial in rural areas where access to specialists may be limited. Furthermore, the development of new treatment modalities, including biologics and targeted therapies, is expected to revolutionize the management of porokeratosis. As these technologies become more integrated into clinical practice, they are likely to drive growth in the porokeratosis market by improving patient outcomes and satisfaction. ### Increased Research and Development Activities The surge in research and development activities focused on skin disorders is a significant driver for the porokeratosis market. In India, academic institutions and pharmaceutical companies are increasingly collaborating to explore new treatment options and understand the underlying mechanisms of porokeratosis. This collaborative effort is expected to yield innovative therapies and improve existing treatment protocols. Moreover, clinical trials for new drugs and therapies are becoming more prevalent, which may enhance the treatment landscape for porokeratosis. The emphasis on research not only aims to address the unmet medical needs of patients but also positions the porokeratosis market for substantial growth as new solutions become available. ### Rising Disposable Income and Healthcare Spending The increase in disposable income among the Indian population is contributing to the growth of the porokeratosis market. As individuals experience higher income levels, they are more inclined to seek medical attention for skin conditions, including porokeratosis. This trend is reflected in the rising healthcare expenditure, which has seen an annual growth rate of approximately 10-12% in recent years. Patients are increasingly willing to invest in advanced treatments and dermatological services, which may lead to a surge in demand for effective therapies. Additionally, the growing middle class in India is likely to prioritize health and wellness, further driving the porokeratosis market as more individuals seek specialized care for skin disorders. ## Future Outlook The [Porokeratosis Market](https://www.marketresearchfuture.com/reports/porokeratosis-market-6067) in India is projected to grow at 11.14% CAGR from 2025 to 2035, driven by increasing awareness and advancements in treatment options. **New opportunities:** - Development of targeted therapies for specific porokeratosis types. - Expansion of telemedicine services for remote consultations. - Investment in clinical trials for innovative treatment modalities. By 2035, the porokeratosis market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Disseminated Actinic Porokeratosis (Largest) vs. Linear Porokeratosis (Fastest-Growing) In the India porokeratosis market, Disseminated Actinic Porokeratosis (DSAP) holds a significant share as it remains the largest segment due to its commonality among populations in sun-exposed areas. This segment represents a considerable proportion of diagnosed cases, underscoring its prominence in treatment demand. Conversely, Linear Porokeratosis, though smaller in market share, is emerging as a fast-growing segment, driven by increased awareness and advancements in treatment options that cater to this condition. The growth trends within this segment indicate a rising incidence of both DSAP and Linear Porokeratosis, attributed to evolving environmental factors and genetic predispositions. The demand for effective treatments continues to surge as healthcare providers and patients become increasingly informed about available therapies. The market is also seeing a boost from ongoing research focused on understanding the underlying mechanisms of these conditions, contributing to more targeted and efficient treatments. Disseminated Actinic Porokeratosis (Dominant) vs. Linear Porokeratosis (Emerging) Disseminated Actinic Porokeratosis (DSAP) is characterized by the presence of multiple, annular plaques primarily affecting sun-exposed areas of the skin. This condition is prevalent among individuals with a history of significant sun exposure, making it a dominant type within the India porokeratosis market. In contrast, Linear Porokeratosis represents an emerging segment, presenting as linear lesions, often noted at birth or in early childhood. Its growing recognition and treatment options are fueled by an increase in clinical awareness and research, paving the way for enhanced therapeutic strategies. Both conditions highlight the diverse presentation of porokeratosis and the need for continued development of specialized treatment protocols. ### By Diagnosis & Treatment: Diagnosis (Largest) vs. Treatment (Fastest-Growing) In the diagnosis segment, the market is largely dominated by traditional methods, which account for a significant share. This includes clinical examinations and skin biopsies that are primarily used to confirm porokeratosis cases. Advanced diagnostic techniques, while emerging, still hold a smaller portion of the overall market share, as familiarity and accessibility of traditional methods continue to shape the landscape. Conversely, the treatment segment is experiencing robust growth due to the increasing awareness and need for effective management of porokeratosis. This growth is driven by advancements in treatment modalities, including topical therapies and photodynamic therapy, which show great promise. Additionally, the rising prevalence of skin conditions is amplifying the demand for innovative treatment options, positioning treatment as an essential focus for the market. Diagnosis: Clinical Examination (Dominant) vs. Treatment: Topical Therapies (Emerging) The clinical examination remains the dominant method in the diagnosis segment due to its established protocols and ease of use. This method provides physicians with immediate insights based on visual inspections and patient history. In contrast, topical therapies are becoming an emerging treatment approach, reflecting a shift towards patient-friendly options that minimize side effects while targeting porokeratosis lesions effectively. The emergence of new formulations and combinations in topical therapies also promises to enhance treatment efficacy, driving a transformation in how patients manage their skin conditions. ### By End-User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) The India porokeratosis market exhibits a diverse end-user landscape. Hospitals and clinics hold a significant portion of the market share, driven by the high volume of patients requiring specialized treatments and consultations. Following closely are diagnostic centers, which play a pivotal role in the detection and diagnosis of porokeratosis, contributing to their notable market presence. Growth trends in this segment are fueled by increasing awareness of skin-related disorders and the rising demand for effective treatment options. Hospitals and clinics are benefitting from advancements in medical technology and improved healthcare infrastructure. In contrast, diagnostic centers are experiencing rapid growth due to the escalating preference for early diagnosis, which is essential for effective treatment, leading to their classification as the fastest-growing segment. Hospitals & Clinics (Dominant) vs. Drug Stores (Emerging) Hospitals and clinics dominate the end-user segment in the India porokeratosis market, characterized by their extensive reach and ability to provide comprehensive healthcare services. These institutions are pivotal in managing patient care, offering specialized dermatological services that are vital for treating porokeratosis. On the other hand, drug stores are emerging as a significant player by making treatments more accessible to the general public. They provide over-the-counter medications and skincare products essential for managing symptoms, tapping into the growing consumer demand for accessible healthcare solutions. This contrast between the dominant hospitals and the emerging drug stores highlights the evolving landscape of care, where both entities play crucial roles in addressing the needs of patients. ## Competitive Benchmarking The porokeratosis market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as Amgen Inc (US), Bristol-Myers Squibb Company (US), and Galderma S.A. (CH) are actively shaping the market dynamics. Amgen Inc (US) has positioned itself as a leader in biopharmaceuticals, focusing on innovative therapies that address unmet medical needs. Bristol-Myers Squibb Company (US) emphasizes its commitment to research and development, particularly in dermatological conditions, while Galderma S.A. (CH) leverages its expertise in dermatology to enhance its product offerings. Collectively, these strategies foster a competitive environment that prioritizes patient-centric solutions and technological advancements.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for diverse product offerings, yet the influence of major companies remains significant, as they set trends and standards that smaller entities often follow. In October Amgen Inc (US) announced a strategic partnership with a leading Indian pharmaceutical firm to enhance the distribution of its dermatological products in the region. This collaboration is likely to bolster Amgen's market presence and improve access to innovative treatments for porokeratosis, reflecting a broader trend of localized partnerships aimed at optimizing market reach. In September Bristol-Myers Squibb Company (US) launched a new clinical trial focused on a novel treatment for porokeratosis, aiming to address the condition's underlying mechanisms. This initiative underscores the company's commitment to advancing research in dermatology and could potentially lead to groundbreaking therapies that reshape treatment paradigms in the coming years. In August Galderma S.A. (CH) expanded its product line with the introduction of a new topical formulation specifically designed for porokeratosis management. This product launch not only diversifies Galderma's portfolio but also indicates a strategic focus on innovation and responsiveness to patient needs, which is crucial in a competitive market. As of November current trends in the porokeratosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming pivotal, as companies recognize the value of collaboration in enhancing research capabilities and market penetration. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, thereby fostering a more resilient and responsive market environment. ## Recent News & Developments Recent developments in the India Porokeratosis Market have shown an increased focus on innovative treatment options and heightened awareness about the condition. Companies such as Lupin, Intas Pharmaceuticals, and Dr. Reddy's Laboratories have been working towards enhancing their product portfolios, incorporating advanced formulations aimed at treating Porokeratosis.  The market has also observed a significant growth trajectory, with noteworthy financial valuations increasing for pharmaceutical companies engaged in dermatological treatments. In September 2023, Hetero Labs announced a collaboration with a leading research institution to advance Drug Development in the dermatological space, emphasizing the importance of research and scientific innovation.  Additionally, in August 2023, Zydus Cadila launched a specialized formulation aimed at managing Porokeratosis, reflecting their commitment to expanding treatment options. There have been minimal merger or acquisition activities directly related to companies in this niche sector in recent months, indicating a stable competitive landscape. In 2022, the market gained momentum as various organizations conducted extensive awareness programs to educate healthcare professionals about Porokeratosis, reinforcing the significance of early diagnosis and treatment in India. ## Report Scope | MARKET SIZE 2024 | 48.4(USD Million) | | --- | --- | | MARKET SIZE 2025 | 53.79(USD Million) | | MARKET SIZE 2035 | 154.64(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.14% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Amgen Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Pfizer Inc (US), Sanofi S.A. (FR), Mylan N.V. (US), Galderma S.A. (CH) | | Segments Covered | Type, Diagnosis & Treatment, End-User | | Key Market Opportunities | Emerging therapies and increased awareness drive growth in the porokeratosis market. | | Key Market Dynamics | Rising awareness and treatment options for porokeratosis drive market growth and competitive dynamics in India. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India porokeratosis market in 2024?** A: The market valuation was $48.4 Million in 2024. **Q: What is the projected market size for the India porokeratosis market by 2035?** A: The projected valuation for 2035 is $154.64 Million. **Q: What is the expected CAGR for the India porokeratosis market from 2025 to 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 11.14%. **Q: Which companies are the key players in the India porokeratosis market?** A: Key players include Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Pfizer Inc, Sanofi S.A., Mylan N.V., and Galderma S.A. **Q: What are the main segments of the India porokeratosis market?** A: The main segments include type, diagnosis & treatment, and end-user. **Q: How much revenue did the Disseminated Actinic Porokeratosis (DSAP) segment generate in 2024?** A: The DSAP segment generated $15.0 Million in 2024. **Q: What is the revenue forecast for the treatment segment by 2035?** A: The treatment segment is projected to reach $116.64 Million by 2035. **Q: What is the revenue contribution of hospitals and clinics in the India porokeratosis market?** A: Hospitals and clinics contributed $20.0 Million in 2024. **Q: How does the revenue of diagnostic centers compare to that of drug stores in 2024?** A: Diagnostic centers generated $10.0 Million, while drug stores generated $8.0 Million in 2024. **Q: What is the revenue range for Punctate Porokeratosis from 2024 to 2035?** A: The revenue for Punctate Porokeratosis is expected to range from $8.4 Million to $31.64 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-porokeratosis-market-56076*